Supernus Pharmaceuticals Share Price (NASDAQ: SUPN)

$42.86

▲

0.86

(2.05%)

Live

Last updated on August 20, 2025 at 11:39 PM IST

$₹

Check the interactive Supernus Pharmaceuticals Stock chart to analyse performance

Supernus Pharmaceuticals stock performance

as on August 20, 2025 at 11:39 PM IST

Today's Low:$42.57
Today's High:$42.86
$42.86
0.68%
Downside
Day's Volatility :0.68%
Upside
0.0%
52 Weeks Low:$29.16
52 Weeks High:$43.73
$42.86
31.96%
Downside
52 Weeks Volatility :33.32%
Upside
1.99%

Supernus Pharmaceuticals Stock Returns

Period	Supernus Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	28.81%	1.5%	0.0%
6 Months	25.39%	-7.1%	0.0%
1 Year	22.07%	-11.4%	0.0%
3 Years	19.1%	2.9%	-9.6%

Supernus Pharmaceuticals Inc Key Stats

Check Supernus Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$42.0
Open	$43.04
Today's High	$42.95
Today's Low	$42.57
Market Capitalization	$2.4B
Today's Volume	$622.7K
52 Week High	$43.73
52 Week Low	$29.16
Revenue TTM	$665.1M
EBITDA	$132.2M
Earnings Per Share (EPS)	$1.15
PE Ratio	36.52
Profit Margin	9.7%
Quarterly Earnings Growth YOY	0.11%
Return On Equity TTM	6.38%

Stock Returns calculator for Supernus Pharmaceuticals Stock including INR - Dollar returns

The Supernus Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Supernus Pharmaceuticals investment value today

Current value as on today

₹1,28,373

Returns

₹28,373

(+28.37%)

Returns from Supernus Pharmaceuticals Stock

₹24,484 (+24.48%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards Supernus Pharmaceuticals Stock

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for Supernus Pharmaceuticals Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Supernus Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
17.27%
Vanguard Group Inc
11.07%
Armistice Capital, LLC
9.27%
Dimensional Fund Advisors, Inc.
5.39%
Macquarie Group Ltd
4.81%
State Street Corp
3.83%

Analyst Recommendation on Supernus Pharmaceuticals Stock

Rating

Trend

Buy

80%Buy

20%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Supernus Pharmaceuticals(by analysts ranked 0 to 5 stars)

Supernus Pharmaceuticals Share Price Target

What analysts predicted

Upside of 0.33%

Target:

$43.00

Current:

$42.86

Supernus Pharmaceuticals share price target is $43.00, a slight Upside of 0.33% compared to current price of $42.86 as per analysts' prediction.

Supernus Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, SUPN stock has moved up by 30.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 149.82M → 165.45M (in $), with an average increase of 9.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -11.82M → 22.49M (in $), with an average increase of 152.6% per quarter
SUPN vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 63.0% return, outperforming this stock by 44.6%

Supernus Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$392.8M	↓ 3.95%
Net Income	$113.1M	↑ 1.86%
Net Profit Margin	28.79%	↑ 1.65%

	FY20	Y/Y Change
Revenue	$520.4M	↑ 32.5%
Net Income	$127.0M	↑ 12.29%
Net Profit Margin	24.39%	↓ 4.4%

	FY21	Y/Y Change
Revenue	$579.8M	↑ 11.41%
Net Income	$53.4M	↓ 57.92%
Net Profit Margin	9.21%	↓ 15.18%

	FY22	Y/Y Change
Revenue	$667.2M	↑ 15.09%
Net Income	$60.7M	↑ 13.64%
Net Profit Margin	9.1%	↓ 0.11%

	FY23	Y/Y Change
Revenue	$607.5M	↓ 8.95%
Net Income	$1.3M	↓ 97.83%
Net Profit Margin	0.22%	↓ 8.88%

	FY24	Y/Y Change
Revenue	$661.8M	↑ 8.94%
Net Income	$73.9M	↑ 5512.84%
Net Profit Margin	11.16%	↑ 10.94%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$143.6M	↓ 12.58%
Net Income	$124.0K	↓ 89.45%
Net Profit Margin	0.09%	↓ 0.63%

	Q2 FY24	Q/Q Change
Revenue	$168.3M	↑ 17.18%
Net Income	$19.9M	↑ 15961.29%
Net Profit Margin	11.83%	↑ 11.74%

	Q3 FY24	Q/Q Change
Revenue	$175.7M	↑ 4.37%
Net Income	$38.5M	↑ 93.3%
Net Profit Margin	21.91%	↑ 10.08%

	Q4 FY24	Q/Q Change
Revenue	$174.2M	↓ 0.87%
Net Income	$15.3M	↓ 60.18%
Net Profit Margin	8.8%	↓ 13.11%

	Q1 FY25	Q/Q Change
Revenue	$149.8M	↓ 13.97%
Net Income	$-11.8M	↓ 177.16%
Net Profit Margin	-7.89%	↓ 16.69%

	Q2 FY25	Q/Q Change
Revenue	$165.5M	↑ 10.43%
Net Income	$22.5M	↓ 290.23%
Net Profit Margin	13.6%	↑ 21.49%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$376.1M	↓ 4.43%

	FY20	Y/Y Change
Profit	$467.9M	↑ 24.42%

	FY21	Y/Y Change
Profit	$504.7M	↑ 7.86%

	FY22	Y/Y Change
Profit	$580.0M	↑ 14.92%

	FY23	Y/Y Change
Profit	$523.7M	↓ 9.7%

	FY24	Y/Y Change
Profit	$583.9M	↑ 11.49%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$106.6M	↓ 13.35%

	Q2 FY24	Q/Q Change
Profit	$129.7M	↑ 21.69%

	Q3 FY24	Q/Q Change
Profit	$138.0M	↑ 6.41%

	Q4 FY24	Q/Q Change
Profit	$148.1M	↑ 7.28%

	Q1 FY25	Q/Q Change
Profit	$134.1M	↓ 9.46%

	Q2 FY25	Q/Q Change
Profit	$127.3M	↓ 5.04%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$143.1M	↑ 10.96%
Investing Cash Flow	$-157.9M	↓ 61.81%
Financing Cash Flow	$3.9M	↓ 98.96%

	FY20	Y/Y Change
Operating Cash Flow	$138.4M	↓ 3.3%
Investing Cash Flow	$-34.7M	↓ 78.03%
Financing Cash Flow	$3.6M	↓ 9.39%

	FY21	Y/Y Change
Operating Cash Flow	$127.1M	↓ 8.14%
Investing Cash Flow	$-81.9M	↑ 136.07%
Financing Cash Flow	$-130.4M	↓ 3764.51%

	FY22	Y/Y Change
Operating Cash Flow	$116.8M	↓ 8.1%
Investing Cash Flow	$-216.7M	↑ 164.5%
Financing Cash Flow	$-10.5M	↓ 91.97%

	FY23	Y/Y Change
Operating Cash Flow	$111.1M	↓ 4.91%
Investing Cash Flow	$268.7M	↓ 224.03%
Financing Cash Flow	$-397.9M	↑ 3697.65%

	FY24	Y/Y Change
Operating Cash Flow	$172.0M	↑ 54.79%
Investing Cash Flow	$-189.9M	↓ 170.65%
Financing Cash Flow	$12.2M	↓ 103.06%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$38.4M	↓ 14.58%
Investing Cash Flow	$-51.6M	↓ 21.76%
Financing Cash Flow	$1.6M	↑ 43.77%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$35.6M	↓ 7.23%
Investing Cash Flow	$-48.6M	↓ 5.87%
Financing Cash Flow	$1.7M	↑ 5.61%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$53.5M	↑ 50.24%
Investing Cash Flow	$-77.0M	↑ 58.48%
Financing Cash Flow	$3.1M	↑ 85.46%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$44.4M	↓ 17.03%
Investing Cash Flow	$-12.6M	↓ 83.59%
Financing Cash Flow	$5.9M	↑ 91.54%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$30.6M	↓ 31.09%
Investing Cash Flow	$37.3M	↓ 395.28%
Financing Cash Flow	$-21.4M	↓ 463.31%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$58.5M	↑ 91.3%
Investing Cash Flow	$-30.6M	↓ 182.02%
Financing Cash Flow	$935.0K	↓ 104.37%

Supernus Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Supernus Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Supernus Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Supernus Pharmaceuticals Inc	26.48%	25.39%	22.07%	19.1%	92.98%
Haleon Plc Spon Ads	2.31%	-2.3%	-1.02%	56.75%	31.58%
United Therapeutics Corporation	6.99%	-17.64%	-9.59%	42.35%	76.36%
Zoetis Inc.	5.63%	-0.62%	-15.21%	-5.68%	-1.7%
Neurocrine Biosciences Inc.	0.78%	16.28%	-11.18%	25.09%	17.46%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Supernus Pharmaceuticals Inc	36.52	36.52	1.47	2.26	0.06	0.02	NA	18.96
Haleon Plc Spon Ads	21.51	21.51	3.09	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.22	12.22	1.43	26.61	0.19	0.13	NA	158.65
Zoetis Inc.	26.84	26.84	2.47	6.32	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	39.29	39.29	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Supernus Pharmaceuticals Inc	Buy	$2.4B	92.98%	36.52	9.7%
Haleon Plc Spon Ads	Buy	$43.4B	31.58%	21.51	13.81%
United Therapeutics Corporation	Buy	$14.2B	76.36%	12.22	40.36%
Zoetis Inc.	Buy	$69.0B	-1.7%	26.84	27.83%
Neurocrine Biosciences Inc.	Buy	$13.2B	17.46%	39.29	13.88%

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Organization	Supernus Pharmaceuticals
Employees	674
CEO	Mr. Jack A. Khattar M.B.A.
Industry	Health Technology

Key Management of Supernus Pharmaceuticals Inc

Name	Title
Mr. Jack A. Khattar M.B.A.	Founder, President, CEO, Secretary & Director
Mr. Timothy C. Dec	Senior VP & CFO
Dr. Padmanabh P. Bhatt Ph.D.	Chief Scientific Officer & Senior VP of Intellectual Property
Mr. Frank Mottola	Senior VP & Chief Technology Operations Officer
Dr. Jonathan Rubin M.B.A., M.D.	Senior VP of Research & Development and Chief Medical Officer
Mr. Kevin T. Anderson Esq.	Compliance Officer
Dr. Todd Horich M.B.A., Ph.D.	Senior Vice President of Marketing, Commercial Operations & Market Access
Mr. Taylor Raiford	Senior Vice President of Sales
Dr. Bryan A. Roecklein Ph.D.	Senior Vice President of Corporate Development
Mr. Jeff Bozick	Senior Vice President of Supply Chain

Important FAQs about investing in SUPN Stock from India :

What is Supernus Pharmaceuticals share price today?

Supernus Pharmaceuticals share price today is $42.86 as on August 20, 2025 at 11:39 PM IST. Supernus Pharmaceuticals share today touched a day high of $42.86 and a low of $42.57.

What is the 52 week high and 52 week low for Supernus Pharmaceuticals share?

Supernus Pharmaceuticals share touched a 52 week high of $43.73 and a 52 week low of $29.16. Supernus Pharmaceuticals stock price today i.e. August 20, 2025 at 11:39 PM IST is trending at $42.86, lower by 1.99% versus the 52 week high.

How to invest in Supernus Pharmaceuticals Stock (SUPN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Supernus Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Supernus Pharmaceuticals Shares that will get you 0.0350 shares as per Supernus Pharmaceuticals share price of $42.86 per share as on August 20, 2025 at 11:39 PM IST.

What is the minimum amount required to buy Supernus Pharmaceuticals Stock (SUPN) from India?

Indian investors can start investing in Supernus Pharmaceuticals (SUPN) shares with as little as ₹87.0225 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in Supernus Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on Supernus Pharmaceuticals share’s latest price of $42.86 as on August 20, 2025 at 11:39 PM IST, you will get 0.2333 shares of Supernus Pharmaceuticals. Learn more about fractional shares .

What are the returns that Supernus Pharmaceuticals has given to Indian investors in the last 5 years?

Supernus Pharmaceuticals stock has given 92.98% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?